These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 16483669)
1. T3 augmentation of SSRI resistant depression. Abraham G; Milev R; Stuart Lawson J J Affect Disord; 2006 Apr; 91(2-3):211-5. PubMed ID: 16483669 [TBL] [Abstract][Full Text] [Related]
2. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Agid O; Lerer B Int J Neuropsychopharmacol; 2003 Mar; 6(1):41-9. PubMed ID: 12899735 [TBL] [Abstract][Full Text] [Related]
4. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. Iosifescu DV; Nierenberg AA; Mischoulon D; Perlis RH; Papakostas GI; Ryan JL; Alpert JE; Fava M J Clin Psychiatry; 2005 Aug; 66(8):1038-42. PubMed ID: 16086620 [TBL] [Abstract][Full Text] [Related]
5. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. Appelhof BC; Brouwer JP; van Dyck R; Fliers E; Hoogendijk WJ; Huyser J; Schene AH; Tijssen JG; Wiersinga WM J Clin Endocrinol Metab; 2004 Dec; 89(12):6271-6. PubMed ID: 15579788 [TBL] [Abstract][Full Text] [Related]
6. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. Łojko D; Rybakowski JK J Affect Disord; 2007 Nov; 103(1-3):253-6. PubMed ID: 17289154 [TBL] [Abstract][Full Text] [Related]
7. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor. Lenox-Smith AJ; Jiang Q Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525 [TBL] [Abstract][Full Text] [Related]
8. Novel Augmentation Strategies in Major Depression. Martiny K Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173 [TBL] [Abstract][Full Text] [Related]
9. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine. Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727 [TBL] [Abstract][Full Text] [Related]
10. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. Azorin JM; Llorca PM; Despiegel N; Verpillat P Encephale; 2004; 30(2):158-66. PubMed ID: 15107719 [TBL] [Abstract][Full Text] [Related]
11. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012 [TBL] [Abstract][Full Text] [Related]
12. [Interest of the use of pindolol in the treatment of depression: review]. Brousse G; Schmitt A; Chereau I; Eschalier A; Dubray C; Llorca PM Encephale; 2003; 29(4 Pt 1):338-50. PubMed ID: 14615704 [TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Baldwin DS; Cooper JA; Huusom AK; Hindmarch I Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138 [TBL] [Abstract][Full Text] [Related]
15. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Cooper-Kazaz R; Apter JT; Cohen R; Karagichev L; Muhammed-Moussa S; Grupper D; Drori T; Newman ME; Sackeim HA; Glaser B; Lerer B Arch Gen Psychiatry; 2007 Jun; 64(6):679-88. PubMed ID: 17548749 [TBL] [Abstract][Full Text] [Related]
16. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. Miner CM; Brown EB; Gonzales JS; Munir R J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723 [TBL] [Abstract][Full Text] [Related]
17. [Use of antidepressant drugs in schizophrenic patients with depression]. Micallef J; Fakra E; Blin O Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Nemeroff CB; Entsuah R; Benattia I; Demitrack M; Sloan DM; Thase ME Biol Psychiatry; 2008 Feb; 63(4):424-34. PubMed ID: 17888885 [TBL] [Abstract][Full Text] [Related]
19. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153 [TBL] [Abstract][Full Text] [Related]
20. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. Arias B; Serretti A; Lorenzi C; Gastó C; Catalán R; Fañanás L J Affect Disord; 2006 Feb; 90(2-3):251-6. PubMed ID: 16356553 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]